Beacon ADC Cited in mAbs Journal

Beacon ADC, an innovative platform for antibody-drug-conjugate (ADC) drug development data, has been cited in a recent mAbs publication titled “Exploration of the antibody-drug conjugate clinical landscape” by Maecker et al, (DOI: 10.1080/19420862.2023.2229101). The study highlights the role Beacon ADC can play in supporting high-quality, data-driven research in the fast-growing field of ADC therapeutics.

The publication provides an in-depth analysis of ADCs, a rapidly growing class of targeted cancer therapies. Researchers relied on Beacon Intelligence’s ADC dataset to assess the current development pipeline, analyze clinical progress, and map emerging trends in ADC technology. The study emphasizes the increasing interest in ADCs as a promising therapeutic modality, with significant advancements in linker chemistry, payload mechanisms, and targeted delivery systems.

ADCs represent a ground-breaking approach in oncology, combining the precision of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. This innovative strategy enables highly selective tumor targeting while minimizing damage to healthy tissues. The mAbs publication underscores the importance of reliable, high-quality data in tracking the evolution of ADC therapeutics, an area where Beacon Intelligence provides unparalleled insights.

Beacon Intelligence’s ADC dataset offers comprehensive coverage of preclinical and clinical-stage ADC programs worldwide. Curated by expert analysts, the platform delivers real-time intelligence on pipeline developments, clinical trial outcomes, and regulatory progress. The dataset is available through Beacon Intelligence’s subscription service, allowing biotech and pharmaceutical companies, as well as academic institutions, to make data-driven decisions in ADC research and development.

Yu-Shin Hsu, Lead Research Analyst, at Beacon Intelligence comments: “Being cited in mAbs reinforces the impact of Beacon ADC’s dataset in supporting ground-breaking research. Our goal is to provide the most accurate and up-to-date intelligence, enabling researchers and industry leaders to navigate the rapidly evolving ADC landscape with confidence.”

What is Beacon ADC?

Beacon ADC is the most comprehensive Antibody-Drug Conjugate (ADC) database available. Providing timely and accurate, market leading, pre-clinical and clinical drug, trial, and commercial intelligence data.

  • The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
  • Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.